Homepage
Author:
Nexalin Technology, Inc.
Posted Date:
April 15, 2026
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Nexalin Technology, Inc.
April 15, 2026
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Technology, Inc.
April 14, 2026
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Nexalin Technology, Inc.
April 9, 2026
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Nexalin Technology, Inc.
February 24, 2026
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Nexalin Technology, Inc.
February 23, 2026
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
Nexalin Technology, Inc.
February 7, 2026
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Nexalin Technology, Inc.
February 2, 2026
Nexalin Technology Receives Nasdaq Listing Status Notification
Nexalin Technology, Inc.
January 28, 2026
